Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase of Trial: Phase I
Latest Information Update: 09 May 2016
At a glance
- Drugs TG 02 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Tragara Pharmaceuticals
- 05 May 2016 Status changed from active, no longer recruiting to completed.
- 10 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Apr 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.